Status:
RECRUITING
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Lead Sponsor:
Adaptimmune
Conditions:
Neoplasms
Eligibility:
All Genders
Phase:
PHASE1
Brief Summary
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Detailed Description
Participants who received a ADP adoptive cell therapy will be enrolled in this non-therapeutic, multi-center, long term follow-up (LTFU) study and will be followed for up to 15 years post-infusion of ...
Eligibility Criteria
Inclusion
- Participants who have received at least one dose of ADP adoptive cell therapy agent.
- Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
- Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
- Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- The investigator is responsible for review of medical history.
- Capable of giving signed informed consent.
Exclusion
- \- None
Key Trial Info
Start Date :
April 9 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2032
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT03391778
Start Date
April 9 2018
End Date
April 1 2032
Last Update
July 3 2024
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University School of Medicine
Atlanta, Georgia, United States, 30322
2
ADP Investigational Site
Baltimore, Maryland, United States, 21201
3
National Cancer Institute - Center for Cancer Research
Bethesda, Maryland, United States, 20892
4
University of Michigan
Ann Arbor, Michigan, United States, 48109